目的 探討止喘靈口服液治療兒童咳嗽變異性哮喘（風(fēng)熱襲肺證）的臨床療效。方法 選取2021年11月—2022年12月在南京中醫(yī)藥大學(xué)附屬醫(yī)院兒科門診就診的60例咳嗽變異性哮喘患兒，按隨機(jī)數(shù)字表法將患兒分為對(duì)照組（33例）和治療組（27例）。對(duì)照組2歲≤患兒年齡＜5歲患兒溫開(kāi)水沖服孟魯司特鈉顆粒，4 mg/次，每晚1次；5歲≤患兒年齡＜14歲患兒咀嚼后吞咽孟魯司特鈉咀嚼片，5 mg/次，每晚1次。治療組口服止喘靈口服液，2歲≤患兒年齡＜3歲，3 mL/次；3歲≤患兒年齡＜9歲，6 mL/次；≥10歲者，10 mL/次，3次/d。兩組均治療2周。觀察兩組的臨床療效，比較兩組主要癥狀評(píng)分、次要癥狀評(píng)分和中醫(yī)證候總評(píng)分。結(jié)果 治療后，治療組患者控顯率是63.0%，顯著高于對(duì)照組的21.2%（P＜0.05）；治療組總有效率是96.3%，對(duì)照組是90.9%，兩組總有效率比較差異無(wú)統(tǒng)計(jì)學(xué)意義。治療后，兩組咳嗽程度評(píng)分、咳嗽頻率評(píng)分、主癥總評(píng)分均較同組治療前顯著降低（P＜0.05）；治療后，治療組主要癥狀評(píng)分顯著低于對(duì)照組（P＜0.05）。治療后，兩組口渴評(píng)分、咽痛評(píng)分、流涕評(píng)分、鼻塞評(píng)分、總評(píng)分均顯著降低（P＜0.05）；治療后，治療組口渴評(píng)分顯著低于對(duì)照組（P＜0.05）。兩組治療1、2周中醫(yī)證候總評(píng)分均較同組治療前顯著降低（P＜0.05）；治療組治療1、2周中醫(yī)證候總評(píng)分顯著低于對(duì)照組（P＜0.05）。結(jié)論 止喘靈口服液治療咳嗽變異性哮喘療效顯著，能夠顯著改善患兒的咳嗽癥狀，可應(yīng)用于兒童咳嗽變異性哮喘風(fēng)熱襲肺證，該藥藥味精簡(jiǎn)，服用方便，安全性好。

Objective To investigate the therapeutic effect of Zhichuanling Oral Liquid in treatment of cough variant asthma in children (wind-heat attacking lung syndrome). Methods A total of 60 children with cough-variant asthma treated in the pediatric outpatient department of the Affiliated Hospital of Nanjing University of Chinese Medicine from November 2021 to December 2022 were selected and divided into control group (33 cases) and treatment group (27 cases) according to random number table method. Patients in the control group were po administered with Montelukast Sodium Oral Granules, children ≤ 2 years old and children < 5 years old were given Montelukast Sodium Granules with warm water, 4 mg/time, once a night. Children ≤ 5 years old Children < 14 years old swallowed Montelukast Sodium Chewable Tablets after chewing, 5 mg/time, once a night. Children in the treatment group were po administered with Zhichuanling Oral Liquid, 2 years≤ children < 3 years, 3 mL/time, 3 years old ≤ children < 9 years, 6 mL/time, ≥10 years old, 10 mL/time, 3 times daily. Both groups were treated for 2 weeks. The clinical efficacy of the two groups was observed, and the main symptom score, secondary symptom score and total TCM syndrome score of the two groups were compared. Results After treatment, the control rate of the treatment group was 63.0%, significantly higher than that of the control group (21.2%) (P < 0.05). The total effective rate was 96.3% in the treatment group and 90.9% in the control group. There was no significant difference between the two groups. After treatment, the score of cough severity, cough frequency and total score of main disease in two groups were significantly decreased compared with that before treatment (P < 0.05). After treatment, the main symptom score of the treatment group was significantly lower than that of the control group (P < 0.05). After treatment, thirst score, throat pain score, runny nose score, nasal congestion score and total score were significantly decreased in two groups (P < 0.05). After treatment, the thirst score of treatment group was significantly lower than that of control group (P < 0.05). The total score of TCM syndromes in two groups after 1 and 2 weeks of treatment was significantly lower than that before treatment (P < 0.05). The total score of TCM syndrome in the treatment group was significantly lower than that in the control group (P < 0.05). Conclusion Zhichuanling Oral Liquid has a remarkable effect in treatment of cough variant asthma in children (wind-heat attacking lung syndrome), and can significantly improve the cough symptoms of children, and can be applied to the wind-heat attack lung syndrome of children with cough variant asthma. The medicine has simple taste, convenient administration and good safety.

R985